

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects



Verona Pharma

Trial	Program	# of Subjects	Duration	Status
Completed 5 studies in 105 subjects with RPL554 initial proof-of-concept solution formulation				
Phase 1/2	SAD MAD study with new suspension formulation	112	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	29	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	30	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	30	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	12	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	403	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (tiotropium/olodaterol; Stiolto Respimat)	~75	Dose twice daily for three days	Started July 2018